These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 32124549)
1. Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group. Aye JM; Chi YY; Tian J; Rudzinski ER; Binitie OT; Dasgupta R; Wolden SL; Hawkins DS; Gupta AA Pediatr Blood Cancer; 2020 May; 67(5):e28243. PubMed ID: 32124549 [TBL] [Abstract][Full Text] [Related]
2. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. Gallego S; Chi YY; De Salvo GL; Li M; Merks JHM; Rodeberg DA; van Scheltinga ST; Mascarenhas L; Orbach D; Jenney M; Million L; Minard-Colin V; Wolden S; Zanetti I; Parham DM; Mandeville H; Venkatramani R; Bisogno G; Hawkins DS; Pediatr Blood Cancer; 2021 Mar; 68(3):e28832. PubMed ID: 33245207 [TBL] [Abstract][Full Text] [Related]
3. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239 [TBL] [Abstract][Full Text] [Related]
4. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group. Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883 [TBL] [Abstract][Full Text] [Related]
5. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739 [TBL] [Abstract][Full Text] [Related]
6. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080 [TBL] [Abstract][Full Text] [Related]
7. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361 [TBL] [Abstract][Full Text] [Related]
8. Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. Raney RB; Anderson JR; Brown KL; Huh WW; Maurer HM; Meyer WH; Parham DM; Rodeberg DA; Wolden SL; Donaldson SS; Pediatr Blood Cancer; 2010 Oct; 55(4):612-6. PubMed ID: 20806360 [TBL] [Abstract][Full Text] [Related]
9. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group. Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144 [TBL] [Abstract][Full Text] [Related]
10. Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group. Aye JM; Xue W; Palmer JD; Walterhouse DO; Arnold MA; Heaton TE; Venkatramani R Pediatr Blood Cancer; 2021 Apr; 68(4):e28914. PubMed ID: 33501771 [TBL] [Abstract][Full Text] [Related]
11. Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R Pediatr Blood Cancer; 2024 Oct; 71(10):e31200. PubMed ID: 39016936 [TBL] [Abstract][Full Text] [Related]
12. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G; Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665 [TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382 [TBL] [Abstract][Full Text] [Related]
14. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Walterhouse DO; Meza JL; Breneman JC; Donaldson SS; Hayes-Jordan A; Pappo AS; Arndt C; Raney RB; Meyer WH; Hawkins DS Pediatr Blood Cancer; 2011 Jul; 57(1):76-83. PubMed ID: 21298768 [TBL] [Abstract][Full Text] [Related]
15. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children]. Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063 [No Abstract] [Full Text] [Related]
16. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060 [TBL] [Abstract][Full Text] [Related]
17. Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. Lautz TB; Chi YY; Tian J; Gupta AA; Wolden SL; Routh JC; Casey DL; Dasgupta R; Hawkins DS; Rodeberg DA Int J Cancer; 2020 Sep; 147(5):1419-1426. PubMed ID: 32012255 [TBL] [Abstract][Full Text] [Related]
19. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R Pediatr Blood Cancer; 2023 Dec; 70(12):e30701. PubMed ID: 37783659 [TBL] [Abstract][Full Text] [Related]
20. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Donaldson SS; Meza J; Breneman JC; Crist WM; Laurie F; Qualman SJ; Wharam M; Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):718-28. PubMed ID: 11597814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]